Author

Gloria González-García

OpenAlex ID: A5015744145

Immunogenicity and safety assessment of a SARS-CoV-2 recombinant spike RBD protein vaccine (Abdala) in paediatric ages 3–18 years old: a double-blinded, multicentre, randomised, phase 1/2 clinical trial (ISMAELILLO study)

2023 · Zurina Cinza-Estévez, Sonia Resik-Aguirre, et al. · EClinicalMedicine · 6

Immunogenicity and Safety Assessment of a SARS-CoV-2 Recombinant Spike RBD Protein Vaccine (Abdala) in Paediatric Ages 3 to 18 Years Old: A Double-Blinded, Multicentre, Randomised, Phase 1/2 Clinical Trial (ISMAELILLO Study)

2022 · Zurina Cinza-Estévez, Sonia Resik-Aguirre, et al. · SSRN Electronic Journal · 1

Works count: 2

Citation count: 7

H-index: 1

I10-index: